Elizaveta Benevolenskaya, PhD

Institution: University of Illinois at Chicago

Project: Why Do Some Cancer Cells Persist Despite Treatment for EGFR Lung Cancer?

Grant(s): Lung Cancer Discovery Award

Many patients with non-small cell lung cancer with a mutation in the EGFR gene initially respond well to the treatment. However, almost all of these cancers progress on therapy, even with recently developed EGFR inhibitor drugs such as osimertinib. Delaying acquired tolerance to EGFR inhibitors would clearly improve patient outcomes. The reason for certain cancer cells being left behind (known as persister cells) when the majority of cancer cells die is unknown. Taking into account the variety of cell response to the drug, we recently used a new approach that allowed us to identify metabolic differences between persister cells. We will study these differences in relation to the main pathway regulating cell response to anti-cancer drugs. We will identify persister vulnerabilities and may find new targets for combination drug therapy.

Asthma Educator Institute
, | Jul 11, 2022
Freedom From Smoking Virtual Clinic
San Jose, CA | Oct 24, 2022